---
title: "Digital-first delivery of GLP-1RA therapy in 8,127 women"
id: "nature-3-real-world-digital-first-delivery-of-glp-1-receptor-agonist-therapy-in-women"
canonical_url: "https://medichelpline.com/clinical-feed/nature-3-real-world-digital-first-delivery-of-glp-1-receptor-agonist-therapy-in-women"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04687-x"
published_at: "2026-10-16T10:17:10.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Digital-first delivery of GLP-1RA therapy in 8,127 women
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-3-real-world-digital-first-delivery-of-glp-1-receptor-agonist-therapy-in-women
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04687-x)
- **Published At:** 2026-10-16T10:17:10.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators reported an observational, digital-first program that delivered **GLP-1RAs** (99.8% **tirzepatide**) to 8,127 women recruited from the community across a UK remote-care pathway. - The onboarding process required supervised identity verification, mandatory baseline biochemical testing and clinician review before medication dispatch. - The program included weekly live-video check-ins, monthly clinician-led reviews, supervised weight confirmation, medication scanning and mandatory monthly questionnaires tied to refill approval. - Mean baseline weight was 104.2 kg (s.d. 19.8); mean BMI 38.2 kg m−2 (s.d. 6.7); 95.5% met criteria for class I–III obesity. - At 6 months mean weight loss was 16.1 kg (15.5% of baseline); 83.1% achieved ≥10% weight reduction and 22.4% achieved ≥20% weight loss. Retention at 6 months was 91.4%. - Among those with paired labs, mean **HbA1c** decreased by 3.3 mmol mol−1; values normalized in 84.5% with diabetes-range baseline and 96.3% with prediabetes. - Lipids improved: total cholesterol down 0.77 mmol l−1, LDL cholesterol down 0.61 mmol l−1, triglycerides down 0.47 mmol l−1. - Investigators observed no serious treatment-related adverse events in the 6-month follow-up. - The study design was observational, single-arm, self-pay and limited to 6 months; investigators noted the absence of a comparator group and that interpretation is constrained by these factors.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04687-x#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04687-x) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women [ Download PDF ](https://www.nature.com/articles/s41591-026-04687-x.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04687-x.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 16 October 2026 # Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women * [John Deanfield](https://www.nature.com/articles/s41591-026-04687-x#auth-John-Deanfield-Aff1) [ORCID: orcid.org/0000-0001-8806-6052](https://orcid.org/0000-0001-8806-6052)[1](https://www.nature.com/articles/s41591-026-04687-x#Aff1), * [Jamie Lai Chun Wong](https://www.nature.com/articles/s41591-026-04687-x#auth-Jamie_Lai_Chun-Wong-Aff2) [ORCID: orcid.org/0000-0002-0052-5144](https://orcid.org/0000-0002-0052-5144)[2](https://www.nature.com/articles/s41591-026-04687-x#Aff2), * [Michail Katsoulis](https://www.nature.com/articles/s41591-026-04687-x#auth-Michail-Katsoulis-Aff2) [ORCID: orcid.org/0000-0002-1756-9530](https://orcid.org/0000-0002-1756-9530)[2](https://www.nature.com/articles/s41591-026-04687-x#Aff2), * [Emma Deanfield](https://www.nature.com/articles/s41591-026-04687-x#auth-Emma-Deanfield-Aff3)[3](https://www.nature.com/articles/s41591-026-04687-x#Aff3), * [Raj Thakkar](https://www.nature.com/articles/s41591-026-04687-x#auth-Raj-Thakkar-Aff4) [ORCID: orcid.org/0000-0003-4811-6865](https://orcid.org/0000-0003-4811-6865)[4](https://www.nature.com/articles/s41591-026-04687-x#Aff4), * [Riyaz Patel](https://www.nature.com/articles/s41591-026-04687-x#auth-Riyaz-Patel-Aff5) [ORCID: orcid.org/0000-0003-4603-2393](https://orcid.org/0000-0003-4603-2393)[5](https://www.nature.com/articles/s41591-026-04687-x#Aff5), * [Rachael Joy](https://www.nature.com/articles/s41591-026-04687-x#auth-Rachael-Joy-Aff6) [ORCID: orcid.org/0009-0007-8984-0602](https://orcid.org/0009-0007-8984-0602)[6](https://www.nature.com/articles/s41591-026-04687-x#Aff6), * [Matthew Noble](https://www.nature.com/articles/s41591-026-04687-x#auth-Matthew-Noble-Aff7) [ORCID: orcid.org/0000-0003-1174-186X](https://orcid.org/0000-0003-1174-186X)[7](https://www.nature.com/articles/s41591-026-04687-x#Aff7) & * … * [Donna H. Ryan](https://www.nature.com/articles/s41591-026-04687-x#auth-Donna_H_-Ryan-Aff8)[8](https://www.nature.com/articles/s41591-026-04687-x#Aff8) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04687-x#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial weight reduction and cardiometabolic benefit in randomized trials; however, prospective implementation evidence from digital care models and female sex community populations remains limited. Here we report outcomes from an observational study of 8,127 women initiating GLP-1RA therapy (99.8% tirzepatide) through a structured digital program incorporating mandatory biochemical monitoring, weekly video-supported follow-up and clinician-guided dose titration in the UK. Mean weight reduction was 16.1 kg (95% confidence interval 15.9 to 16.2; _P_ < 0.001), representing 15.5% of baseline weight; 83.1% achieved ≥10% and 22.4% achieved ≥20% weight loss, with consistent responses across age, baseline weight and socioeconomic strata. Among participants with paired biomarker data, mean glycated hemoglobin decreased by 3.3 mmol mol−1 (95% confidence interval 3.1 to 3.4; _P_ < 0.001), normalizing in 84.5% of those with baseline diabetes-range values and 96.3% with prediabetes, and lipid parameters improved significantly (reductions in total cholesterol of 0.77 mmol l−1, low-density lipoprotein cholesterol of 0.61 mmol l−1 and triglycerides of 0.47 mmol l−1). Retention was 91.4% at 6 months, with no serious treatment-related adverse events. These findings support the feasibility of delivering structured, digitally enabled obesity pharmacotherapy at scale and provide prospective real-world implementation evidence for this care model. Interpretation is limited by the observational design, absence of a comparator group, self-pay population and 6-month follow-up. ### Explore related subjects Discover the latest articles and news in related subjects. * [Health care](https://www.nature.com/subjects/health-care) * [Risk factors](https://www.nature.com/subjects/risk-factors) ## Main Obesity represents a major global public health challenge and is a key driver of type 2 diabetes, cardiovascular disease, hepatic dysfunction and multiple chronic conditions that contribute to impaired quality of life and substantial healthcare and economic burden. Excess adiposity, particularly visceral and ectopic fat deposition, plays a central role in cardiometabolic disease pathogenesis, underscoring the need for effective and scalable strategies to reduce body fat and associated risk[1](https://www.nature.com/articles/s41591-026-04687-x#ref-CR1 "Obesity and overweight. WHO fact sheet. WHO https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight \(2025\)."),[2](https://www.nature.com/articles/s41591-026-04687-x#ref-CR2 "NCD Risk Factor Collaboration \(NCD-RisC\). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027–1050 \(2024\)."). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and related incretin-based therapies have transformed the therapeutic landscape for obesity management. Initially developed for diabetes treatment, these agents have demonstrated clinically meaningful weight loss, improvements in cardiometabolic risk factors and favorable clinical outcomes in large randomized trials of individuals with overweight and obesity, including those without diabetes[3](https://www.nature.com/articles/s41591-026-04687-x#ref-CR3 "Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 \(2021\)."),[4](https://www.nature.com/articles/s41591-026-04687-x#ref-CR4 "Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 \(2022\)."),[5](https://www.nature.com/articles/s41591-026-04687-x#ref-CR5 "Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 \(2023\)."). The expanding population eligible for therapy presents an opportunity to reduce substantially obesity-related disease burden, but delivery at scale poses challenges for healthcare systems largely configured around in-person care models. In many settings, access to GLP-1RAs remains restricted to individuals with advanced obesity or diabetes, contributing to increasing uptake through community and self-pay pathways[6](https://www.nature.com/articles/s41591-026-04687-x#ref-CR6 "Lingvay, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31, 111–122 \(2023\)."),[7](https://www.nature.com/articles/s41591-026-04687-x#ref-CR7 "Overweight and obesity management \(NG246\). NICE https://www.nice.org.uk/guidance/ng246 \(2025\)."),[8](https://www.nature.com/articles/s41591-026-04687-x#ref-CR8 "Tirzepatide for managing overweight and obesity \(TA1026\). NICE https://www.nice.org.uk/guidance/ta1026 \(2024\)."). Individuals accessing therapy through these routes may differ from trial populations with respect to comorbidity burden, treatment behaviors, dosing patterns and metabolic characteristics. Large cardiometabolic outcomes trials in obesity have also enrolled predominantly male populations despite women representing the majority of GLP-1RA users in routine and community care[6](https://www.nature.com/articles/s41591-026-04687-x#ref-CR6 "Lingvay, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31, 111–122 \(2023\)."). Digitally delivered care models offer a potential alternative framework for treatment delivery, but robust real-world evidence with this approach remains limited[9](https://www.nature.com/articles/s41591-026-04687-x#ref-CR9 "Xie, Y. et al. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951–962 \(2025\)."),[10](https://www.nature.com/articles/s41591-026-04687-x#ref-CR10 "Do, D. et al. GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes. JAMA Netw. Open 7, e2413172 \(2024\)."),[11](https://www.nature.com/articles/s41591-026-04687-x#ref-CR11 "Gasoyan, H. et al. One-year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Netw. Open 7, e2433326 \(2024\)."),[12](https://www.nature.com/articles/s41591-026-04687-x#ref-CR12 "Golovaty, I. & Hagan, S. Direct-to-consumer platforms for new anti-obesity medications - Concerns and potential opportunities. N. Engl. J. Med. 390, 677–680 \(2024\)."). The majority of previously reported platforms operate as transactional prescribing services with limited additional features. The limitations and concerns around these approaches have been well articulated and a set of standards proposed[12](https://www.nature.com/articles/s41591-026-04687-x#ref-CR12 "Golovaty, I. & Hagan, S. Direct-to-consumer platforms for new anti-obesity medications - Concerns and potential opportunities. N. Engl. J. Med. 390, 677–680 \(2024\)."). Our program complies with these and, in addition, has several integrated and protocol-driven components that, taken together, constitute a structured clinical–digital hybrid model that more closely replicates the safety and oversight features of specialist in-person care. These include mandatory monthly structured questionnaire completion as a condition of medication refill approval, weekly live-video check-ins with trained proctors, supervised weight confirmation and medication scanning. Monthly clinician-led review enabled individualized, response-guided dose titration rather than automatic escalation. Furthermore, a proactive structured side effect mitigation package was provided alongside evolving educational content, which was available throughout the program. We report outcomes from this large-scale digital program that delivered GLP-1RA therapy to more than 8,000 women recruited from a community-based population over a 6-month period. The inclusive design enabled evaluation of treatment response across age, baseline weight, socioeconomic strata and ethnicity. This study is one of the largest real-world evaluations of GLP-1RA therapy in a female sex community cohort and provides evidence to complement trial findings, while informing implementation of digitally supported obesity care at scale. ## Results ### Study population Between 27 November 2024 and 31 January 2025, adult women (female sex at birth) were recruited through digital outreach and screened via a structured online onboarding platform incorporating demographic characteristics, anthropometry, medical history, medication use and contraindications to GLP-1RA therapy (Fig. [1](https://www.nature.com/articles/s41591-026-04687-x#Fig1)). **Fig. 1: Participant flow through screening, eligibility and inclusion.** ![Fig. 1: Participant flow through screening, eligibility and inclusion.](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04687-x/MediaObjects/41591_2026_4687_Fig1_HTML.png) [Full size image](https://www.nature.com/articles/s41591-026-04687-x/figures/1) A flow diagram illustrating participant recruitment, eligibility screening, baseline assessment and inclusion in the analytic cohort. Individuals were screened via a structured digital onboarding platform. Individuals were only included if they had completed baseline biochemical testing, and were excluded if clinical review identified abnormalities in blood test results or contraindications to therapy. The final analytic cohort comprised participants prescribed and dispatched GLP-1RA therapy before the administrative cutoff. Of 16,121 individuals meeting initial screening criteria, 4,025 were not included solely owing to noncompletion of baseline blood testing, and a further 308 were excluded following clinical review, owing to abnormal laboratory findings or medical exclusion criteria. GLP-1RA therapy was prescribed and dispatched to a total of 8,127 participants before an administrative cutoff date, and they were then included in the analytic cohort (Fig. [1](https://www.nature.com/articles/s41591-026-04687-x#Fig1), Table [1](https://www.nature.com/articles/s41591-026-04687-x#Tab1) and Extended Data Table [1](https://www.nature.com/articles/s41591-026-04687-x#Tab2)). This represents consecutive selection across eligibility confirmation, laboratory completion and clinical review stages within a fully remote care pathway. **Table 1 Baseline characteristics of the study population stratified by baseline body weight** [ Full size table](https://www.nature.com/articles/s41591-026-04687-x/tables/1) ### Baseline characteristics The program was designed exclusively for adult women (female sex at birth), and sex at birth was determined through structured self-reporting during onboarding, confirmed via supervised identity verification. Table [1](https://www.nature.com/articles/s41591-026-04687-x#Tab1) and Extended Data Table [1](https://www.nature.com/articles/s41591-026-04687-x#Tab2) outline baseline participant characteristics according to weight and age groups, respectively. Mean baseline weight was 104.2 kg (s.d. of 19.8) and mean body mass index (BMI) 38.2 kg m−2 (s.d. of 6.7), with 95.5% of participants meeting criteria for class I–III obesity. Weight distribution was broad, with 19.3% of participants weighing ≥120 kg and 25.9% <90 kg. The cohort spanned a wide adult age range (18–79 years), with 82.1% aged 30 to <60 years. Mean baseline total cholesterol was 5.7 mmol l−1 (s.d. of 1.2), low-density lipoprotein (LDL) cholesterol 3.8 mmol l−1 (s.d. of 1.1) and glycated hemoglobin (HbA1c) 36.2 mmol mol−1 (s.d. of 6.1), values consistent with cardiometabolic profiles reported in community populations with obesity without established cardiovascular disease. Age-stratified analyses demonstrated modest increases in metabolic risk with advancing age, with 21.3% of participants aged ≥60 years meeting criteria for type 2 diabetes or prediabetes compared to 4.1% of those aged 18 to <30 years. Participants were predominantly white (88.0%), although representation across other ethnic groups enabled subgroup analyses of treatment response. Socioeconomic distribution was heterogeneous, with 37.6% residing within the two most deprived Index of Multiple Deprivation (IMD) quintiles. Of the 8,127 participants initiating therapy, 7,297 (89.8%) provided weight measurements at 6
## Related Clinical Research

- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [No Patient Left Behind: Expanding Semaglutide’s Reach](https://medichelpline.com/clinical-feed/endocrine-news-21-no-patient-left-behind-expanding-semaglutide-s-reach.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.